| Gene symbol | TERT | Synonyms | CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1, TP2, TRT, hEST2, hTRT | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5p15.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | telomerase reverse transcriptase | ||||
| GTO ID | GTC1397 |
| Trial ID | NCT01456065 |
| Disease | Ovary Epithelial Cancer |
| Altered gene | TERT |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | IMP |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | A Phase I, Open, Randomized, Study to Investigate the Safety of Active Immunotherapy With Fully Mature, TERT-mRNA and Survivin - Peptide Double Loaded Dendritic Cells (DCs) in Subjects With Advanced Epithelial Ovarian Cancer, Enrolled in the Study Within Twelve Weeks After Completing Primary Therapy |
| Year | 2010 |
| Country | Austria|Hungary |
| Company sponsor | Life Research Technologies GmbH |
| Other ID(s) | LRT-I-L01 Ovar |
| Vector information | |||
|
|||
| Cohort1: 8 vial weekly | |||||||||
|
|||||||||
| Cohort2: 8 vial biweekly | |||||||||
|
|||||||||